Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $94.1 million, marking a 35% year-over-year growth with 31% organic growth. The company raised its full-year revenue guidance to $348-$352 million, implying a 29%-30% total revenue growth. COVID-related revenues contributed approximately 14% to quarterly revenue and 55% to growth. Repligen also completed the acquisition of Non-Metallic Solutions and plans to acquire ARTeSYN Biosolutions, enhancing its systems strategy.
Repligen Corporation (NASDAQ:RGEN) announced a definitive agreement to acquire ARTeSYN Biosolutions for approximately $200 million, enhancing its portfolio of single-use downstream bioprocessing systems. The acquisition is expected to generate around $30 million in pro forma revenue for ARTeSYN in 2020 and contribute $33 to $36 million in 2021, with breakeven adjusted earnings per share in the same year and accretive results anticipated in 2022. This move complements previous acquisitions of Engineered Molding Technologies and Non-Metallic Solutions, positioning Repligen as a leading player in the bioprocessing market.
Repligen Corporation (NASDAQ:RGEN) will announce its third quarter 2020 financial results on November 5, 2020, before the market opens. A conference call will take place at 8:30 a.m. EST to discuss the results and business updates. Investors can access the call by phone or via a webcast on the company’s Investor Relations page. Repligen is a global life sciences company focused on developing bioprocessing technologies that enhance the manufacturing of biological drugs.
Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $87.5 million, a year-over-year increase of 24% with 19% organic growth. The company raised its fiscal year revenue guidance to $332-$340 million, reflecting anticipated margins expansion and continued demand amid COVID-19 vaccine programs. Gross margin improved to 57.9%, with EPS rising to $0.30 from $0.17 a year ago. The acquisition of Engineered Molding Technology supports RGEN's strategic focus on expanding its single-use portfolio.
On June 15, 2020, Repligen Corporation (NASDAQ:RGEN) announced the appointment of Carrie Eglinton Manner to its Board of Directors. With over 23 years in the healthcare sector, she brings extensive leadership experience, notably as Senior VP at Quest Diagnostics and former President & CEO at GE Healthcare. Her expertise in business growth and profitability is expected to support Repligen's innovation-based strategy. The Board expressed confidence in her ability to enhance company operations and expand its market presence in bioprocessing technologies.
Repligen Corporation (NASDAQ:RGEN) reported record Q1 2020 revenue of $76.1 million, a 25% increase year-over-year, driven by 16% organic growth. The company achieved a GAAP gross margin of 58.0%, with GAAP EPS of $0.18. Adjusted EPS rose to $0.32, reflecting strong demand in gene therapy and chromatography sectors. The company maintains its 2020 revenue guidance of $309-$319 million, projecting a 14%-18% overall growth. Optimistic outlook amid COVID-19 efforts, focusing on employee safety while maintaining operational stability.